Edition:
United States

Cempra Inc (CEMP.O)

CEMP.O on Nasdaq

7.75USD
9 Dec 2016
Change (% chg)

$0.40 (+5.44%)
Prev Close
$7.35
Open
$7.40
Day's High
$8.00
Day's Low
$7.35
Volume
986,352
Avg. Vol
1,671,399
52-wk High
$32.31
52-wk Low
$5.70

CEMP.O

Chart for CEMP.O

About

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's... (more)

Overall

Beta: 1.05
Market Cap(Mil.): $385.00
Shares Outstanding(Mil.): 52.38
Dividend: --
Yield (%): --

Financials

  CEMP.O Industry Sector
P/E (TTM): -- 40.79 30.35
EPS (TTM): -2.03 -- --
ROI: -54.52 -0.56 15.27
ROE: -62.40 -1.20 16.60

U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

The effectiveness of Cempra Inc's antibiotic to treat community-acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration narrowly concluded on Friday.

Nov 04 2016

UPDATE 2-U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

Nov 4 The effectiveness of Cempra Inc's antibiotic to treat community-acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration narrowly concluded on Friday.

Nov 04 2016

U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

Nov 4 The effectiveness of Cempra Inc's experimental antibiotic to treat community acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration concluded on Friday.

Nov 04 2016

BRIEF-Cempra stock trading halted today FDA advisory committee to discuss Solithromycin

* Cempra stock trading halted today; FDA advisory committee to discuss solithromycin

Nov 04 2016

FDA highlights liver safety issues in Cempra drug review

Cempra Inc's experimental drug to treat community-acquired pneumonia, the kind recently suffered by presidential candidate Hillary Clinton, causes a potentially concerning rise in liver enzymes, according to a preliminary review by the U.S. Food and Drug Administration.

Nov 02 2016

UPDATE 1-U.S. FDA highlights liver safety issues in Cempra drug review

Nov 2 Cempra Inc's experimental drug to treat community-acquired pneumonia, the kind recently suffered by presidential candidate Hillary Clinton, causes a potentially concerning rise in liver enzymes, according to a preliminary review by the U.S. Food and Drug Administration.

Nov 02 2016

U.S. FDA highlights liver safety issues in Cempra drug review

Nov 2 Cempra Inc's experimental drug to treat community acquired pneumonia, the kind suffered by presidential candidate Hillary Clinton recently, causes a potentially concerning rise in liver enzymes, according to a preliminary review by the U.S. Food and Drug Administration.

Nov 02 2016

BRIEF-Cempra receives $10 mln milestone payment from Toyama Chemical

* Cempra receives $10 million milestone payment from Toyama Chemical (a subsidiary of fujifilm holdings corporation) as solithromycin progresses to phase 3 studies in Japan Source text for Eikon: Further company coverage:

Nov 01 2016

BRIEF-Cempra reports Q3 2016 results and provides corporate update

* Cempra reports third quarter 2016 financial results and provides corporate update

Oct 27 2016

BRIEF-Cempra - EMA's CHMP will begin their assessment of Solithromycin

* Cempra announces European medicines agency validates MAA for solithromycin for treatment of CABP

Aug 23 2016

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,532 +6.00
Johnson & Johnson (JNJ.N) $112.33 +1.34
Pfizer Inc. (PFE.N) $31.75 +0.81
Roche Holding Ltd. (ROG.S) CHF227.80 +7.40
Roche Holding Ltd. (RO.S) CHF231.00 +4.90
Abbott Laboratories (ABT.N) $39.26 +0.58
Bayer AG (BAYGn.DE) €94.54 +1.37
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.33 +1.25
AstraZeneca plc (AZN.L) 4,280.00p +164.00

Earnings vs. Estimates